| NCT ID | NCT05080166 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 74 participants |
| Start Date | 2022-02-08 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 74 participants in total. It began in 2022-02-08 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.
Eligibility Criteria
Inclusion Criteria: Lymphoma Survivors Phase 1 and 2: * Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma) * Age ≥ 18 years * Interval of 3 months to 24 months from completion of first-line treatment * In complete remission after first line of treatment * Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity Subscale \[FCRI-SS). * Access to computer (for videoconferencing) Lymphoma clinicians and mental health clinicians Phase 1: * Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR mental health clinicians (psychologists, social workers, psychiatrists) ≥ 1 year from completion of clinical training. * Longitudinal clinical care for patients with lymphoma by oncologists OR provision of care for patients with cancer by mental health clinicians Exclusion Criteria: Lymphoma Survivors Phase 1: * Age \< 18 years * Concurrent other malignancy * Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorder (as ascertained from medical record screen). Lymphoma Survivors Phase 2: * Age \< 18 years * Concurrent other malignancy * Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorders (as ascertained from medical record screen). * Our study will exclude members of the following special populations: * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners
Contact & Investigator
Oreofe O Odejide, MD, PhD
PRINCIPAL INVESTIGATOR
Oreofe_Odejide@dfci.harvard.edu
Frequently Asked Questions
Who can join the NCT05080166 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05080166 currently recruiting?
Yes, NCT05080166 is actively recruiting participants. Contact the research team at Oreofe_Odejide@dfci.harvard.edu for enrollment information.
Where is the NCT05080166 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05080166 clinical trial?
NCT05080166 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Oreofe O Odejide, MD, PhD at Oreofe_Odejide@dfci.harvard.edu. The trial plans to enroll 74 participants.